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Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or
lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow
Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft
yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients’ disease stage and
condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation
outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan),
prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34+
cell count in PB before apheresis. Determination of the CD34+ cell count in PB before apheresis helps to identify patients at risk of
poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach
might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents.
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INTRODUCTION
Autologous haematopoietic SCT (auto-HSCT) aims to restore BM
function after high-dose chemotherapy. In the context of
auto-HSCT, mobilised PBSCs are currently the preferred source
of HSCs worldwide for adult patients with multiple myeloma (MM)
and lymphoma (non-Hodgkin’s and Hodgkin’s lymphoma).1–3
Auto-HSCT with PBSCs is favoured because it leads to faster
engraftment and haematologic reconstitution versus BM
infusion, resulting in potentially improved patient outcomes.1
Moreover, some studies demonstrated that the use of PBSCs
was associated with better quality of life and reduced total
costs.1,2,4,5
HSCs usually circulate in a very small number in PB;6 therefore,
their mobilisation from BM to PB is an essential part of auto-HSCT
programs. Cytokines such as G-CSF, alone or in combination with
chemotherapy, are typically used for PBSC mobilisation.1,2,7
Compared with G-CSF-based mobilisation, chemo-mobilisation
(i.e., chemotherapy+G-CSF) has advantages in terms of putative
antitumour effect and higher probability of obtaining grafts with a
sufficient CD34+ cell count with lower numbers of aphereses.1,7
However, disadvantages of chemo-mobilisation include increased
toxicity and morbidity, and the need for hospitalisation (depend-
ing on the chemotherapy schedule; e.g., cyclophosphamide-based
mobilisation is possible in an outpatient setting).1,7
Despite widespread and established practice, current mobilisa-
tion strategies vary between centres and differ in terms of
feasibility and outcome.2,7 Although the majority of patients are
able to mobilise sufficient CD34+ cells for at least a single
autograft, approximately 15% fail to do so.8 If two autografts are
needed for a specific treatment strategy, even more patients fail to
reach their individual collection goal. Newer approaches aiming to
optimise mobilisation procedures include off-label use of pegy-
lated G-CSF,9–12 erythropoietin,13 SCF14,15 and plerixafor.16–18
Nevertheless, it is necessary to optimise the current mobilisation
approaches and to identify upfront the patients at risk of
mobilisation failure.
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PURPOSE AND METHOD
This review generated by 28 experts from the European Group for
Blood and Marrow Transplantation (EBMT) attempted to develop a
position statement on best approaches for auto-HSC mobilisation
in patients with MM and lymphoma, on factors predictive of poor
mobilisation or mobilisation failure and on potential optimisation
options for poor mobilisers. The position statement is based on
currently available literature and clinical practice of the
expert group.
OVERVIEW OF CURRENT AUTO-HSC MOBILISATION
APPROACHES
Steady-state (cytokines only)
Monotherapy with G-CSFs remains the only available option for
steady-state mobilisation, as GM-CSF is no longer available in
many countries after commercial failure and withdrawal. G-CSF
treatment leads to granulocyte activation/expansion and release
of various proteases, eventually resulting in cleavage of
cell–extracellular adhesion molecules that retain HSCs in BM.6
Currently, the G-CSF cytokines filgrastim and lenograstim have
marketing authorisation for mobilisation of auto-HSCs in
Europe.19,20 The approved doses/schedules are filgrastim
10 μg/kg per day subcutaneously for 5–7 consecutive days and
lenograstim 10 μg/kg per day subcutaneously for 4–6 days;
leukapheresis should be performed on days 5 or 6 (filgrastim)
and between days 5 and 7 (lenograstim). Mobilisation with
cytokines alone (Figure 1a) is well tolerated, but their use can be
limited by the feasibility of embedding them into individual,
study-based treatment plans or by suboptimal PBSC yields.
Chemo-mobilisation
Adding chemotherapeutic agents to cytokines may increase PBSC
yields and can further decrease tumour burden.1,7 However, the
PBSC mobilisation window is less predictable compared with
steady-state approaches,1,7 causing potential problems with
apheresis scheduling. In addition, the incidence and severity of
side effects with chemotherapy+G-CSF is increased compared
with G-CSF alone.21–23 The approved doses for PBSC mobilisation
after myelosuppressive chemotherapy are filgrastim 5 μg/kg per
day subcutaneously and lenograstim 150 μg/m2 per day (i.e.,
therapeutically equivalent of 5 μg/kg per day subcutaneously),
starting within 1–5 days after completion of chemotherapy until
last leukapheresis.19,20
Chemotherapy-based mobilisation may be part of the disease-
specific chemotherapy (Figure 1b) or of separate chemo-
therapeutic course(s) in addition to disease-specific treatment
(Figure 1c). The choice of a specific chemo-mobilisation approach
is based on patient disease characteristics and on local clinical
practice guidelines (Table 1). In MM patients, high-dose cyclopho-
sphamide+G-CSF is probably the most commonly used chemo-
mobilisation strategy,21,23 whereas some studies also suggest
etoposide-based mobilisation approaches.24 With the advent of
new therapeutic agents, such as proteasome inhibitors and
immunomodulatory drugs,25 the role of high-dose cyclopho-
sphamide as therapeutic agent in MM now becomes more
questionable given its relatively small antitumour effect.26 In
lymphoma patients, chemotherapy+G-CSF as part of the disease-
specific induction and salvage regimens has always been the
preferred method. Such approach can eliminate the need for
additional chemo-mobilisation or steady-state mobilisation before
auto-HSCT in these heavily treated patients.27–30 Furthermore,
these disease-specific chemotherapy combinations have been
shown to be more effective than cyclophosphamide-based
chemo-mobilisation.29,30
Plerixafor
Plerixafor, a novel chemokine-receptor (CXCR4) antagonist,
disrupts the interaction between stromal-deriving factor 1 and
CXCR4, thereby enhancing the HSC mobilisation effect of G-CSF.31
In Europe, plerixafor is approved for use in combination with
G-CSF for auto-HSC mobilisation in patients with lymphoma or
MM whose cells mobilise poorly.32 The approved dose is 240 μg/
kg per day subcutaneously 6–11 h before initiation of apheresis
following 4-day G-CSF pretreatment.
Plerixafor plus G-CSF alone or G-CSF+chemotherapy has been
shown to be effective and well tolerated in patients with MM or
lymphoma, including poor mobilisers, with superior efficacy to
G-CSF alone or G-CSF+chemotherapy.13,16,17,33–37 Numerous
studies reported that plerixafor plus G-CSF is effective as rescue
therapy during HSC mobilisation.36,38–41 Whether the addition of
plerixafor results in a benefit for patients in terms of clinical


























Figure 1. Current auto-HSCT mobilisation strategies: steady-state
mobilisation (a; cytokines alone), chemotherapy-based mobilisation
using disease-specific chemotherapy (b) or separate mobilisation
chemotherapy (c).
Table 1. Current chemo-mobilisation approaches (selection based on
clinical practice of the expert group)






ABVD, BEACOPP, (R)-CHOP, (R)-DA-EPOCH,
(R)-DHAP, carbo-DHAP, dexa-BEAM,
(R)-ESHAP, (R)-mini-BEAM, (R)-ICE, IVE,
R-ACVBP, R-bendamustine, VIM
Abbreviations: ABVD=doxorubicin, bleomycin, vinblastine, dacarbazine;
ACVBP=doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone;
BEACOPP=bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, prednisone; BEAM=BCNU, etoposide, ara-C
(cytarabine), melphalan; CAD= cyclophosphamide, doxorubicin, dexa-
methasone; carbo= carboplatin; CHOP= cyclophosphamide, doxorubicin,
vincristine, prednisone; DA-EPOCH=dose-adjusted etoposide, prednisone,
vincristine, cyclophosphamide, doxorubicin; Dexa=dexamethasone;
DHAP=dexamethasone, ara-C, cisplatin; DPACE=dexamethasone,
platinum, doxorubicin, cyclophosphamide, etoposide; ESHAP= etoposide,
methylprednisolone, ara-C, cisplatin; ICE= ifosfamide, carboplatin,
etoposide; IVE= ifosfamide, etoposide, epirubicin; MM=multiple myeloma;
R= rituximab; VDT-PACE=bortezomib, dexamethasone, thalidomide,
cisplatin, doxorubicin, cyclophosphamide, etoposide; VIM= etoposide,
ifosfamide, mitoxantrone.
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OPTIMISING GRAFT ‘QUANTITY’ (CD34+ CELL YIELD)
Mobilisation regimen
In clinical practice, filgrastim and lenograstim may be used
interchangeably and modifications of the approved label may be
applied depending on local guidelines and treatment plans.
Higher G-CSF doses (⩾10 μg/kg per day) or alternate application
schedules (two times 5 μg/kg per day instead of one time
10 μg/kg per day) have been investigated to further enhance the
number of harvested auto-HSCs.42,43 However, further research is
required. In addition, high G-CSF doses may increase the risk
of splenic rupture.44 As mentioned above, CD34+ cell yields can be
further increased by mobilisation with chemotherapy+G-CSF
compared with G-CSF monotherapy.21–23 The addition of
plerixafor to standard mobilisation strategies has been shown
to increase CD34+ cell yields in known or predicted poor
mobilisers.13,16,17,33–37,39,40
Timing
The timing of mobilisation regimen administration and apheresis
may also influence CD34+ cell yields. Recent data suggest that
auto-HSC collection efficacy is higher and the proportion of
patients with optimal harvest is larger when G-CSF is given
3 h before apheresis versus administration on the evening before
apheresis.45 Nevertheless, further research is needed to confirm
these data. Plerixafor was shown to mobilise adequate auto-HSC
yields when administered as rescue treatment before or during
apheresis in patients with insufficient auto-HSC mobilisation after
G-CSF monotherapy or chemo-mobilisation.38–41 Earlier detection
of PBSC mobilisation (based on CD34+ cell-count assessments on
day 4 versus 5) can help determine whether plerixafor should be
administered, and has been suggested to further decrease the risk
of mobilisation failure.46
Technical aspects
The flow cytometry protocol for CD34+ cell measurement is
a critical step in monitoring the HSC mobilisation process.47
A validated protocol and external quality control are
recommended.48 CD34+ cell collection has been shown to be
more efficient with larger apheresis volumes (4.0–5.3 times the
patient’s total blood volume)49,50 and no difference in CD34+ cell
viability was observed compared with normal-volume apheresis
(2.7–3.5 times the patient’s total blood volume).49 Therefore,
enhanced volumes are recommended for apheresis in relatively
poor mobilisers or patients with high individual CD34+ cell
collection goal (⩾3 transplants). For patients who still mobilise
poorly with larger-volume approaches, plerixafor addition to
standard mobilisation strategies may sufficiently enhance mobi-
lisation efficacy.51 Nevertheless, not all patients are eligible for
enhanced volume strategies. Larger transfusion volumes and
related higher DMSO contents have been associated with
increased risk of cardiac side effects.52
Position statement on current auto-HSC mobilisation approaches
and their optimisation
Auto-HSC mobilisation approaches for MM and lymphoma
patients suggested by the expert group are shown in Figure 2. If
required, strategies are recommended to be optimised by
remobilising with cytokines alone or by changing the previously
chosen chemo-mobilisation approach (e.g., switch from steady-
state to chemo-mobilisation, or choose an alternative chemo-
mobilisation strategy if patients failed to mobilise after an initial
chemotherapy-based approach). In addition, new agents such as
plerixafor or the use of large-volume apheresis can further
improve mobilisation outcomes. For the latter, processing of up
to three times the total blood volume is suggested as feasible
without impairing the patient’s tolerance.
The optimal time to start apheresis is more predictable for
patients mobilised with G-CSF alone than for those mobilised with
chemotherapy+G-CSF. For patients who were mobilised with
chemotherapy+G-CSF and showed too low CD34+ counts on the
estimated day of apheresis, the expert group suggests reassessing
CD34+ counts after 1 day. This ensures that leukapheresis is
started on the optimal day. Up to four leukapheresis sessions can
be recommended as feasible. However, the group raised the issue





Decision to use steady-state or chemo-mobilisation should be based on local guidelines
However, sufficient CD34+ cell yields are less likely with steady-state mobilisation
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Disease-specific chemotherapy approaches are suggested to avoid the burden
of additional chemotheraphy cycles
Steady-state mobilisation may be an option for selected patients:
- Patients in complete remission





Figure 2. Position statement: PBSC mobilisation strategies for MM (a) and lymphoma patients (b). *G-CSF only; †G-CSF+chemotherapy; §higher
doses of cyclophosphamide may be used based on available data; however, the aim should be to keep the duration of neutropenia as short as
possible.
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AUTOGRAFT ‘QUALITY’
Cell subsets other than CD34+ cells
Recent data suggest that the quality of CD34+ cells from poor
mobilisers is comparable to those from adequate mobilisers in
patients treated with filgrastim;53 the dose of mobilised CD34+
cells per kg mainly determines neutrophil and platelet engraft-
ment after auto-HSCT.54 The addition of plerixafor to G-CSF alone
or G-CSF+chemotherapy not only mobilises more CD34+ cells but
also seems to increase the proportion of more-primitive HSC
subsets, the absolute lymphocyte count and the numbers of
various lymphocyte subsets (CD19+ B lymphocytes, CD3+
T cells and natural killer (NK) cells) in the autograft.55–59
Preliminary data suggest a positive correlation between the
number of reinfused NK cells and early absolute lymphocyte
recovery after auto-HSCT.60 However, further investigation is
needed to evaluate potential effects of autograft cell subsets on
the patients’ clinical outcomes.
Tumour cell contamination
Auto-HSCT is associated with the risk of tumour cell contamination
of the graft. Current mobilisation strategies with G-CSF or G-CSF
+chemotherapy vary not only in auto-HSC yields and safety, but
also in levels of autograft contamination with tumour cells.61–66
Whether the antitumour effect of chemo-mobilisation also
translates into a lower risk of tumour cell contamination,
compared to steady-state mobilisation, remains controversial.62
The integration of novel agents into mobilisation regimens so far
does not appear to increase tumour cell contamination of the
graft.67,68 A large currently ongoing trial (Collaboration between
EBMT and Genzyme to collect Autologous transplant outcomes in
Lymphoma and Myeloma patients (CALM)) will compare the
outcomes of patients transplanted with plerixafor-mobilised cells
between 2008 and 2011 to those of equivalent patients
transplanted without plerixafor to determine whether plerixafor
mobilises increased rates of malignant cells (data to be published;
patients will be followed until 2014). The impact of autograft
tumour cell contamination on long-term safety and clinical
outcome is still controversial.62 Randomised phase III studies
suggest that tumour cell contamination of the graft does not
significantly affect PFS or OS.5,62–64,69–71 On the other hand, results
from a report of the Centre for International Blood and Marrow
Transplant Research indicate that syngeneic transplants lead to
better outcome than autologous transplants, suggesting that
contamination is a problem in myeloma and probably also in
lymphoma.72,73 It should also be noted that most clinical trials in
MM patients were performed before the recent implementation of
novel treatments. Therefore, in vivo tumour debulking may be
much higher today, resulting in a higher potential of contami-
nated autografts and reinfused tumour cells inducing relapse. This
makes it difficult to draw definitive conclusions on the role of
residual plasma cells and ex vivo purging.
Position statement on autograft ‘quality’
Determination of cell subsets other than CD34+ cells is not
routinely performed in clinical practice, but only in clinical trials.
Accordingly, assessment of tumour cell contamination in routine
clinical practice may not be valuable but can be of interest in
clinical trials.
FACTORS PREDICTIVE OF POOR MOBILISATION OR
MOBILISATION FAILURE
Factors described as predictive of impaired HSC collection or
mobilisation failure include: older age; female sex; diagnosis
(lymphoma worse than MM); longer time since diagnosis; more
advanced disease; previous radiotherapy and/or chemotherapy
(especially fludarabine and other purine analogues, and melpha-
lan); higher number of previous therapy lines; longer time from
last chemotherapy to mobilisation initiation; previous auto-HSCT;
low haemoglobin, WBC, or platelet levels before mobilisation; and
low CD34+ cell counts in BM before mobilisation and in PB before
apheresis.74–88 Whether prior treatment with new therapies such
as lenalidomide and rituximab negatively affects the mobilisation
outcomes in MM and lymphoma patients, respectively, is
controversial.77,78,82,84,89–91 Adaptation of the mobilisation strat-
egy and/or the addition of novel agents (e.g., plerixafor) to
conventional regimens may overcome the negative effect
of prognostic factors for poor mobilisation.24,27,34–36,92–94
Nevertheless, there is an urgent need to define which patient
population might benefit from optimised mobilisation approaches
to help clinical decision-making.
Algorithms to define poor mobilisers
In a retrospective analysis of 840 patients with MM or non-
Hodgkin’s lymphoma, 129 patients (15%) were identified as poor
mobilisers and divided into three categories based on CD34+
levels in PB before leukapheresis: ‘borderline’ poor mobilisers
(11–19/μL at maximum stimulation), ‘relative’ poor mobilisers
(6–10/μL) and ‘absolute’ poor mobilisers (o5/μL).8 Diagnosis, sex,
age, body weight and previous irradiation made no significant
difference in HSC mobilisation capacity. Only the number of
previous chemotherapy cycles and prior melphalan treatment had
a significant impact on the ability to mobilise HSCs. In another
retrospective analysis of 1556 patients with lymphoproliferative
disorders initially mobilised with G-CSF alone, sensitivity–
specificity analysis was used to identify ideal PB CD34+ count
cut-points that would allow early intervention and prevent
collection failure.86 In patients with plasma cell disorders, PB
CD34+ counts of 11, 17, 21 and 28/μL by day 4 or 5 were required
to collect a minimum of 2, 4, 8 or 12 × 106 CD34+ cells per kg,
respectively. A CD34+ yield o0.8 × 106 cells per kg on day 1 of
apheresis was predictive of o2 × 106 CD34+ cells per kg. For
patients with non-Hodgkin’s or Hodgkin’s lymphoma, PB CD34+
counts of o6 and o15/μL on day 4 or 5 predicted failure
to achieve a target collection of 2 and 4× 106 cells per kg,
respectively.
The Gruppo Italiano Trapianto di Midollo Osseo proposed a
definition of poor mobilisers in lymphoma and MM patients using
an analytic hierarchical process.94 Patients are defined as ‘proven’
poor mobilisers when (1) after adequate mobilisation (G-CSF
10 μg/kg if used alone or ⩾ 5 μg/kg after chemotherapy),
the circulating CD34+ cell peak is o20/μL for up to 6 days
after mobilisation with G-CSF or up to 20 days after G-CSF
+chemotherapy, or (2) they yield o2.0 × 106 CD34+ cells per kg in
⩽ 3 aphereses. Patients are ‘predicted’ poor mobilisers if they
(1) failed a previous collection attempt, (2) previously received
extensive radiotherapy or full courses of therapy affecting HSC
mobilisation and (3) meet two of the following criteria: advanced
disease (⩾2 lines of chemotherapy), refractory disease, extensive
BM involvement or cellularity o30% at the time of mobilisation,
and age ⩾ 65 years.
Several groups have developed algorithms to guide the use of
plerixafor.85,95–97 Costa et al.97 developed and validated a
decision-making algorithm based on the PB CD34+ cell count on
day 4 of G-CSF administration and the collection target of CD34+
cells to guide cost-effective use of plerixafor for auto-HSC
mobilisation (continuing G-CSF only or adding plerixafor). Subse-
quently, they showed that patient-adapted plerixafor use based
on this algorithm was superior to cyclophosphamide plus growth
factor98 and successfully mobilised HSCs in MM patients
previously treated with lenalidomide.99 Abhyankar et al.95 devel-
oped a risk-based approach to optimise HSC collection with
plerixafor by identifying potential poor mobilisers upfront. The
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plerixafor algorithm takes into account the number of circulating
CD34+ cells per μL on day 5 of G-CSF mobilisation, the desired
number of CD34+ cells per kg needed per transplant (⩾2.5 × 106/
kg for 1 transplant and ⩾ 5 × 106/kg for >1 transplants), and the
day-1 CD34+ collection yield. A day-5 CD34+ circulating level of
o10 cells per μL (for 1 transplant), or o20 cells per μL (for >1
transplant), or a day-1 CD34+ collection of less than one-half of the
total CD34+ dose needed, prompted the use of plerixafor. Data
demonstrated that this approach helped decrease the need for
remobilisation and reduce the number of collection days needed.
Position statement on predictive factors for poor mobilisation,
CD34+ cell-count determination and proactive intervention to
rescue PBSC collection
Factors considered by the expert group to be predictive of poor
mobilisation in MM and lymphoma patients in daily clinical
practice are listed in Table 2. Of these, the CD34+ cell count in PB
before apheresis is the most robust predictor for poor PBSC
collection.8,85,86,100 Thus, determination of CD34+ cell counts in PB
before apheresis is suggested by the expert group to estimate the
patient’s risk of poor PBSC collection and to consider additional
intervention for patients at risk (Figure 3). For patients with
>20 CD34+ cells per μL in PB before apheresis, no proactive
intervention is needed, whereas the group suggests pre-emptive
use of plerixafor to reach a minimum cell target of 2 × 106 CD34+
cells per kg body weight for patients with o10 CD34+ cells per μL
in PB before apheresis. For patients with 10–20 CD34+ cells per μL
at the mobilisation peak before apheresis (i.e., grey zone), a
dynamic approach is suggested, also taking into account other
previously published predictive factors (Table 2) and the target
number of aphereses before applying plerixafor (e.g., when
collecting PBSCs for ⩾ 2 transplants in MM patients, pre-emptive
intervention with plerixafor may become mandatory for patients
with 10–20 CD34+ cells per μL before apheresis). These sugges-
tions are to be considered the minimum number of CD34+ cells
for auto-HSCT. Higher CD34+ cell counts before auto-HSCT may
reduce the need of post-HSCT support. The EBMT ‘Haematopoietic
Stem Cell Mobilisation and Apheresis’ handbook recommends




accessed on 19 November 2013).
In the opinion of the expert group robust validation of these
factors in a prospective registration trial is desirable. Although
several algorithms were recently proposed to predict PBSC
collection failure using PB CD34+ counts before leukapheresis as
threshold to stratify patients at risk and to trigger proactive
intervention with plerixafor,8,85,86,95–97,100 there is a need for
optimised algorithms to predict apheresis yields based on
circulating CD34+ cell numbers. Also, readily available, robust,
and harmonised techniques for such CD34+ cell number
determination are required.
CONCLUSIONS
PBSC mobilisation can be optimised with an appropriate strategy
adapted to each patient, based on the patient’s disease and
treatment features and the individual collection goal. A low CD34+
cell count in PB before apheresis is a candidate predictor for poor
PBSC collection. The expert group suggested that determination
of CD34+ cell counts before apheresis may estimate the patient’s
risk for poor PBSC collection and may allow proactive intervention
to rescue mobilisation failure.
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More advanced stage 83,85,100
Prior chemotherapy
Higher no. of prior treatment lines 8,75,83,85,88,100





Low CD34+ cell count in PB before apheresis 8,75,85,86
Low platelet count before mobilisation
(controversial)
75,79–81,88
CD34+ cell count prior to apheresis








Apheresis (target cell count = 2.0 Mio CD34+ cells/kg BW)†
Figure 3. Position statement: proactive intervention to rescue
mobilisation failure. *No proactive intervention required; †a target
cell count of >2.0 Mio CD34+ cells per kg body weight (BW) may be
needed depending on the patient’s disease and treatment features,
and the individual collection goal.
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